This Movember, find out how AI-assisted robotic prostatectomy uses imaging, robotics, and deep learning to support prostate cancer treatment.
Robotic prostatectomy has advanced into an informed, precise, and personalised procedure. Now as robotic platforms evolve, artificial intelligence (AI) is beginning to support surgical planning, anatomical recognition, intraoperative guidance, and performance assessment.
For this Movember (Men’s Health Month), these developments deserve special attention because the quality of any cancer treatment must be measured by disease control and the lives patients can lead after surgery.
Image
Advances in Over Three Decades of Robotic Surgery
Prostate cancer remains the most diagnosed cancer in men.
For those patients with localised disease, radical prostatectomy can offer an important treatment option. The operation removes the prostate gland and, where clinically indicated, surrounding tissue and lymph nodes.
However, such a procedure involves a difficult balance. Surgeons must remove tumour tissue while protecting the structures responsible for urinary continence and erectile function.
The prostate sits close to the bladder, urethra, and delicate neurovascular bundles. These nerves and blood vessels play an important role in erectile function.
Their location and the extent to which cancer has spread can vary between patients. A surgical approach that preserves these structures in one patient may not be appropriate for another.
Almost three decades ago, robot-assisted radical prostatectomy (RARP) changed how surgeons approach this challenge.
Robotic systems provide magnified, three-dimensional views of the operating field, articulated instruments, and improved control of fine movements. The surgeon operates from a console, directing the robotic instruments rather than performing the procedure autonomously.
Such an operation extends the surgeon’s ability to work within a confined anatomical space. Yet robotic dexterity alone cannot resolve every clinical uncertainty.
Surgeons still need to interpret imaging, identify tumour boundaries, assess the risk of cancer extending beyond the prostate, and decide how much tissue to preserve.
This is where AI may provide a great opportunity.
By analysing medical images, patient information, and surgical video, AI systems can help convert complex data into information that supports decisions before, during, and after surgery.
“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."
Image
How Can AI Support the Robotic Surgery Workflow?
AI is not the only feature of robotics-assisted surgical approaches.
This approach describes several applications that can support different stages of the prostatectomy pathway. Their value depends on the quality of the underlying data and how well the technology fits the surgeon’s workflow.
Preoperative planning and risk assessment
Before surgery, clinicians combine MRI findings, biopsy results, prostate-specific antigen (PSA) levels, and other patient information to assess the extent and characteristics of the disease.
AI models can analyse these inputs to estimate risks such as extraprostatic extension, or where cancer has spread beyond the prostate capsule.
More detailed, side-specific risk assessments can help surgeons plan nerve-sparing strategies. Rather than treating the two sides of the prostate as identical, clinicians can consider whether the evidence supports preserving the neurovascular bundles on each side.
By preserving nerves, this surgery can support postoperative sexual function, but leaving cancerous tissue behind carries an oncological risk. AI-supported assessment aims to make that decision more informed.
Intraoperative anatomical recognition
Computer vision models can analyse images from surgical cameras and identify structures within the operating field.
These systems use techniques such as deep learning and semantic segmentation to distinguish anatomical features and surgical instruments.
A 2024 study explored real-time anatomical segmentation using images selected from 120 robotic prostatectomy videos. The model achieved a mean Dice score of 0.85 across the test data. Recognition performance varied by structure, with particularly strong results for surgical instruments and lower performance for some anatomical features.
Such a system, while demonstrating itself as a potential important source of structured information, has limited value it recognises an instrument accurately but cannot necessarily identify a nerve, vessel, or tumour boundary with the same reliability.
Image
Augmented reality and surgical guidance
Another emerging application combines AI with three-dimensional imaging and augmented reality (AR). Preoperative scans can be used to create anatomical models that help surgeons understand the position of the tumour and nearby structures.
When integrated into the surgical view, these models can provide additional orientation during dissection. This is particularly relevant when surgeons are attempting to preserve neurovascular structures while maintaining adequate cancer clearance.
The aim is not to replace the surgeon’s view with a digital reconstruction, but, rather to add information that may be difficult to interpret from the live camera image alone.
Training and performance assessment
AI can also analyse recorded operations to identify surgical stages, instrument movements, and patterns associated with technical performance. This could support more consistent training and help experienced surgeons review complex procedures.
A review of prostatectomy research published in 2025 described an AI model that identified key stages of robotic procedures with 92.8% overall concordance against expert annotations.
Improving Outcomes for Patients
The strongest argument for AI in prostatectomy will come from evidence that improves outcomes that matter to patients.
Surgeons and healthcare providers need to know whether AI-supported procedures improve cancer control, reduce complications, or help men recover urinary and sexual function.
A notable development is the prospective, multicentre RIDERS trial, which compared three-dimensional AI-assisted augmented reality guidance with conventional cognitive MRI guidance during nerve-sparing robotic prostatectomy.
The study enrolled 133 patients with suspected extracapsular extension or tumour bulging on preoperative MRI, and the reported results are encouraging.
The AI-AR group had a lower overall positive surgical margin rate than the comparison group, at 22% versus 39%.
Postoperative radiotherapy was also less frequent, at 18% versus 35%. At 12 months, 91% of patients in the AI-AR group had recovered zero-pad urinary continence, compared with 71% in the comparison group.
However, potency recovery and short-term biochemical recurrence rates were similar between the groups.
The wider evidence base also needs context.
A 2026 review of AI in robot-assisted radical prostatectomy describes applications in risk prediction, augmented reality, surgical video analysis, and outcome forecasting.
It highlights promising results, but also identifies limited external validation, inconsistent endpoints, and differences between robotic platforms as barriers to routine adoption.
These limitations matter when assessing which technology to use in healthcare procedures.
A model trained on procedures performed at one centre may not perform equally well in another hospital. Differences in patient populations, imaging protocols, surgical techniques, and equipment can affect its accuracy.
AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.
Image
Robotic Platforms Are Advancing, but Technology Is Not the Outcome
AI is developing alongside changes in robotic hardware.
Single-port systems, for example, allow surgeons to operate through one access point rather than several separate incisions. The approach may reduce postoperative pain, improve cosmetic outcomes, and shorten hospital stays in selected settings.
The choice of robotic platform is also complex and some are already in clinical practice. A 2025 network meta-analysis compared four platforms: da Vinci, KangDuo, Hugo, and Hinotori. It included 2,064 patients across 15 studies.
The analysis found differences in some rankings and individual measures, including operative time. However, it did not identify statistically significant differences between platforms across several major outcomes, including positive surgical margins, length of hospital stay, and early urinary continence.
It is most likely that surgeon experience, institutional resources, and patient factors remain important when selecting a system.
The surgeon, the equipment, the imaging, the software, the training programme, and the clinical pathway all matter for improving patient outcomes.
A potential AI-enabled surgical tool should be assessed against practical questions:
Does the system improve a clearly defined clinical decision or task?
Has it been tested across different hospitals, patient groups, and surgical teams?
Can clinicians understand when the model is uncertain or performing poorly?
Does it integrate safely into existing workflows without distracting the surgical team?
Are patient outcomes measured over a meaningful period, including cancer control and functional recovery?
Procurement decisions should follow clinical evidence, not the novelty of the technology. This is especially important as robotic systems require substantial investment in equipment, training, maintenance, and software integration.
Image
Men’s Health in Focus
Movember provides an opportunity to connect technological progress with the wider experience of men affected by prostate cancer.
Earlier diagnosis, informed treatment decisions, and appropriate follow-up remain essential. Surgical innovation should support these priorities rather than distract from them.
For patients, the most meaningful question is not whether a surgeon uses a robotic system or an AI-enabled console. But whether the chosen treatment offers an appropriate balance between cancer control, recovery, and quality of life.
AI could help surgeons make more individualised decisions about tumour boundaries, nerve preservation, and surgical technique. It could also support more consistent training and provide structured feedback that helps teams improve.
Yet these benefits depend on reliable data, transparent performance, and human oversight.
Clear governance is also needed for any software updates, data protection, and responsibility when AI recommendations influence clinical decisions.
The opportunity lies in supporting skilled professionals with better information, while keeping patient outcomes at the centre of adoption.
At Pharmatica, we examine the technologies, clinical strategies, and innovations shaping the future of healthcare. Our Insights connect emerging evidence with the operational and strategic decisions that directly influence patient care.
Pharmatica: Insight. Connection. Impact.
Frequently Asked Questions
What is AI-assisted robotic prostatectomy?
AI-assisted robotic prostatectomy combines surgeon-controlled robotic surgery with AI tools that can support planning, anatomical recognition, image guidance, risk assessment, and surgical performance analysis. The surgeon remains responsible for the operation and clinical decisions.
How does AI improve robotic prostate cancer surgery?
AI can analyse imaging and patient data to help assess tumour location and the risk of cancer extending beyond the prostate. During surgery, computer vision and augmented reality tools can provide additional anatomical information. These applications aim to support precision and informed decision-making.
Can AI help preserve urinary continence and erectile function after prostatectomy?
AI-guided planning and intraoperative imaging may help surgeons make more informed decisions about tissue and nerve preservation. Early trial findings have reported improved urinary continence in one AI-guided approach, but evidence for consistent improvements in erectile function remains limited.
Is AI-guided prostatectomy better than conventional robotic surgery?
Some clinical findings are encouraging, including results from the RIDERS trial. However, the evidence is still developing. Outcomes vary by procedure, patient characteristics, surgical team, and technology. AI should currently support, rather than replace, clinical judgement.
What are the main risks of using AI in robotic prostate surgery?
Key concerns include inaccurate anatomical recognition, limited testing across different hospitals, biased training data, and poor integration into surgical workflows. Clinical oversight, independent evaluation, and long-term outcome monitoring remain essential.
Nicole (BSc Molecular Medicine, Honours Medical Biochemistry) has many years of pharmaceutical experience, having worked for top CROs and biopharma companies for more than a decade.
Did you enjoy the content?
0
Why not support
Nicole Dale
by giving this content a like
Where Healthcare AI Investment Is Going — And Where It Isn't
The data is out: Two-thirds of AI healthcare startup investment went to just three domains. Insight into clinical leadership, gender inclusivity, and geographical access reveals a sector building for investability… not clinical need.
The AI Bioweapons Risk: We Cannot Afford to Look Away
The risk of AI being used to create a bioweapon is a serious concern for pharma biosecurity after researchers found AI-designed toxins can evade DNA screening. Here’s what you need to know about the AI and bioweapons risk.
AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.
Can Large Language Models Solve More Rare Disease Genomes?
LLM-assisted rare disease re-assessment improves genomic analysis, increasing diagnostic yield and supporting clinician-led precision medicine and possibly drug development.
Comments (0)